Floatz logo

Dfn-15

Pleural Malignancies

National Cancer Institute (NCI)Phase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Pleural Malignancies cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Memorial Sloan Kettering Cancer Center
Phase 1/2CCC
Pembrolizumab
Memorial Sloan Kettering Cancer Center
Phase 1/2CCC
Icasp9M28Z T Cell Infusions
Memorial Sloan Kettering Cancer Center
Phase 1/2CCC
Allogenic tumor Cell Vaccine (K562)
National Cancer Institute (NCI)
Phase 1CC
FAPi-46
Jonsson Comprehensive Cancer Center
Phase 1CC
Epigenetically Modified Autologous Tumor
National Cancer Institute (NCI)
Phase 1CC
Doxepin
Mayo Clinic
Phase 2C
mt027
Suzhou Maximum Bio-tech Co., Ltd.
Phase 1NR

Same molecule, other indications

Dfn-15 is also rated in:

osteoarthritis, hipDormant
BB
Indicative ·
71 / 100
View asset →
osteoarthritis, kneeDormant
BB
Indicative ·
69 / 100
View asset →
ArthritisDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →